JPP Journal of Pharmacy and Pharmacology

JPP 2004, 56: 1707

ISSN 0022-3573

Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin

Leah M. Hesse, Yumiko Sakai, Daesety Vishnuvardhan, Albert P. Li, Lisa L. von Moltke and David J. Greenblatt

Erratum

The publishers would like to apologise to the authors and readers for the error introduced into Figure 2B of the above paper (*J. Pharm. Pharmacol*. (2003) **55**: 1229–1239). The correct Figure 2B is shown below.



Figure 2B Effect of bupropion (■) or rifampicin (◆) on CYP3A4 activity. Various concentrations of inducer (bupropion at 0.1–100 μM or rifampicin at 10–100 μM), as shown on the x-axis, were dissolved in cell media and incubated with hepatocytes from donor 1. The y-axis shows triazolam hydroxylation velocity (CYP3A4 activity) as compared with vehicle control (0.5 % DMSO). Error bars denote standard deviations (n = 3 or 4). $*P < 0.05$, $***P < 0.001$, CYP activity of cells treated with rifampicin vs CYP activity of cells treated with bupropion.

Department of Pharmacology and Experimental Therapeutics and the Department of Biochemistry, Tufts University School of Medicine, Boston, MA 02111, USA

Leah M. Hesse, Daesety Vishnuvardhan, Li, Lisa L. von Moltke, David J. Greenblatt

In Vitro Technologies, Inc., Baltimore, MD 21227, USA

Yumiko Sakai, Albert P. Li

Correspondence: D. J. Greenblatt, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111 USA.
E-mail: DJ.Greenblatt@tufts.edu